MEGURI Research
The Psychedelic Renaissance
From ancient shamanic rituals to FDA clinical trials — psychedelic compounds are reshaping our understanding of consciousness, healing, and spiritual experience.
$8.7B
Projected Market by 2029
Data Bridge Market Research 2023
130+
Active Clinical Trials
ClinicalTrials.gov 2024
12,591
Academic Papers on Psychedelics
OpenAlex 2026
687
Papers on Psilocybin Therapy
OpenAlex 2026 (psychedelic therapy + psilocybin)
67%
Report Mystical Experiences
Johns Hopkins Psilocybin Study
5,000+
Years of Indigenous Use
Archaeological evidence (Tassili n'Ajjer)
What Is the Psychedelic Renaissance?
After nearly five decades of prohibition and stigma, psychedelic substances are experiencing an unprecedented revival in scientific research, clinical practice, and cultural discourse. Between 2017 and 2024, over $2 billion in venture capital flowed into psychedelic startups. Major universities — Johns Hopkins, Imperial College London, NYU, UC Berkeley, Yale, University of Zurich — have established dedicated research centers. The conversation has shifted from 'Are psychedelics dangerous?' to 'How can we use them responsibly?'
This is not a new phenomenon. Humans have used psychoactive plants and fungi for millennia. Cave paintings in Algeria's Tassili n'Ajjer plateau (~7000 BCE) depict figures with mushroom-like objects. The Rigveda (c. 1500 BCE) praises Soma, an unidentified psychoactive sacrament. The Eleusinian Mysteries of ancient Greece — the most prestigious initiation rite in the Mediterranean world for 2,000 years — likely involved an ergot-based psychedelic potion (kykeon). What we call the 'psychedelic renaissance' is, in a deeper sense, a remembering.
Major Psychedelic Compounds
Each substance has a distinct pharmacology, cultural history, and therapeutic profile. Understanding these differences is essential for responsible engagement.
The most studied psychedelic compound in modern clinical research. Johns Hopkins University's Center for Psychedelic & Consciousness Research (est. 2019) demonstrated that a single high-dose session produced sustained decreases in depression and anxiety in cancer patients, with 80% showing clinically significant improvement at 6-month follow-up (Griffiths et al. 2016). Imperial College London's Centre for Psychedelic Research found psilocybin therapy comparable to escitalopram (SSRI) for major depressive disorder (Carhart-Harris et al. 2021). FDA granted Breakthrough Therapy designation for psilocybin-assisted therapy for treatment-resistant depression in 2018 (COMPASS Pathways) and major depressive disorder in 2019 (Usona Institute). Over 200 species of psilocybin-producing mushrooms exist worldwide. Traditional use documented in Aztec 'teonanacatl' ceremonies and Mazatec healing rituals (Maria Sabina).
MAPS (Multidisciplinary Association for Psychedelic Studies) conducted Phase 3 clinical trials for MDMA-assisted therapy for PTSD. Results showed 71% of participants no longer met PTSD diagnostic criteria after three sessions (Mitchell et al. 2021, Nature Medicine). However, the FDA declined approval in August 2024, citing concerns about trial methodology, blinding integrity, and potential cardiac risks. MAPS has since restructured as Lykos Therapeutics and is working with FDA on a path forward. MDMA was originally synthesized by Merck in 1912, gained use in psychotherapy in the 1970s-80s (notably by Alexander 'Sasha' Shulgin and Leo Zeff), and was scheduled in 1985. It primarily works by releasing serotonin, dopamine, and oxytocin, creating what researchers describe as a 'window of tolerance' for processing traumatic memories.
A DMT-containing brew traditionally prepared by indigenous peoples of the Amazon basin. Combines Banisteriopsis caapi vine (containing MAO inhibitors) with Psychotria viridis leaves (containing DMT). The brew produces 4-6 hour visionary experiences. Two Brazilian churches — Santo Daime (founded 1930) and União do Vegetal (UDV, founded 1961) — use ayahuasca as a sacrament and have won legal protections in Brazil, the US, and several European countries. Ayahuasca tourism has boomed in Peru, Ecuador, and Colombia, raising concerns about cultural appropriation, safety (contraindications with SSRIs can be fatal), and exploitation of indigenous knowledge. Observational studies report reductions in depression, anxiety, and substance dependence (Palhano-Fontes et al. 2019, Psychological Medicine).
Synthesized by Albert Hofmann at Sandoz Laboratories in 1938; psychoactive effects discovered accidentally in 1943 ('Bicycle Day,' April 19). Between 1950-1965, over 1,000 clinical papers were published and approximately 40,000 patients received LSD-assisted therapy before it was banned. Contemporary research has resumed: microdosing (5-20µg, sub-perceptual doses taken every 3 days) gained popularity in Silicon Valley, though controlled studies (Szigeti et al. 2021) suggest much of the benefit may be placebo. Full-dose studies show promise for anxiety, depression, and alcohol use disorder (Krebs & Johansen 2012). LSD works primarily on serotonin 5-HT2A receptors and produces effects lasting 8-12 hours. The substance catalyzed the 1960s counterculture and influenced figures from Steve Jobs to Francis Crick.
N,N-DMT (dimethyltryptamine) is found in hundreds of plant species and is endogenously produced in mammalian brains (Barker 2018, Frontiers in Neuroscience), though its biological function remains debated. When smoked or injected, DMT produces an intense 10-15 minute experience often described as encountering 'entities' or entering other dimensions. Rick Strassman's 1990s research at the University of New Mexico (documented in 'DMT: The Spirit Molecule') found that 49% of subjects reported contact with 'beings.' 5-MeO-DMT, found in the venom of the Bufo alvarius (Colorado River toad) and several plant species, produces a distinct experience often described as 'ego dissolution' or 'oceanic boundlessness.' A single inhalation has shown rapid and sustained anti-depressant effects (Davis et al. 2019). Ethical concerns surround Bufo alvarius harvesting, as wild populations are declining.
Derived from the root bark of Tabernanthe iboga, a shrub native to Central West Africa. Central to the Bwiti spiritual tradition of Gabon, Cameroon, and the Republic of Congo. A powerful psychoactive experience lasting 24-36 hours, described as a 'life review' or 'waking dream.' Observational evidence suggests ibogaine can interrupt opioid addiction, with some studies reporting 50-80% of subjects abstaining from opioids at 1-month follow-up (Brown & Alper 2018). However, ibogaine carries significant cardiac risks (QT prolongation) and has been associated with fatalities. Legal for addiction treatment in New Zealand, Mexico, Brazil, and parts of Europe. The Bwiti people express growing concern about exploitation of their sacred plant and ceremonies by the global wellness industry.
Originally developed as an anesthetic in 1962, ketamine is the only psychedelic-adjacent substance currently legal for psychiatric use in most countries. The FDA approved esketamine (Spravato, intranasal S-ketamine) in 2019 for treatment-resistant depression. Off-label IV ketamine infusion clinics have proliferated across the US, with an estimated 500+ clinics operating by 2024. Ketamine works on NMDA glutamate receptors (distinct from classical psychedelics' serotonergic mechanism), producing dissociative states at sub-anesthetic doses. A single infusion can produce rapid antidepressant effects within hours (Zarate et al. 2006, Archives of General Psychiatry). Concerns include potential for abuse, bladder toxicity with chronic use, and variable quality across commercial clinics. It sits at the intersection of psychiatry, psychedelic therapy, and the commercial wellness industry.
The mystical experience is the atom bomb of the mind.
— Stanislav Grof
The Neuroscience of Psychedelics
The academic study of psychedelics has grown dramatically. OpenAlex, the largest open index of scholarly works, records 12,591 papers on psychedelics and 687 specifically on psilocybin therapy — a number that has accelerated sharply since 2017. Among the most influential is the REBUS (Relaxed Beliefs Under Psychedelics) model, proposed by Robin Carhart-Harris and Karl Friston in their 2019 paper "REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics" (Pharmacological Reviews, cited 1,078 times). The REBUS model proposes that psychedelics work by relaxing the precision weighting of high-level priors (beliefs, assumptions, mental models) in the brain's predictive hierarchy, allowing bottom-up sensory information to flow more freely. This ‘anarchic’ state may explain why psychedelics can break rigid patterns of thought seen in depression, addiction, and OCD.
Another landmark paper — "Psychedelics and Psychedelic-Assisted Psychotherapy" (American Journal of Psychiatry, 2020) — provided a comprehensive clinical review that helped legitimize the field within mainstream psychiatry. Together, these works represent a paradigm shift: psychedelics are no longer fringe science but a rapidly maturing discipline with rigorous methodology and institutional backing.
The Mystical Experience Questionnaire (MEQ30)
Developed by Barrett et al. (2015) at Johns Hopkins, the MEQ30 quantifies the 'spiritual' dimension of psychedelic experiences. Based on Walter Pahnke's original work during the 1962 Good Friday Experiment, it identifies five factors that define a 'complete mystical experience.' Studies consistently show that the strength of the mystical experience — not the dose — predicts therapeutic outcomes.
Unity / Interconnectedness
Sense of merging with a larger whole, dissolution of boundaries between self and other. The most commonly reported feature of psychedelic mystical experiences (>80% of high-dose sessions).
Transcendence of Time & Space
Sense that time has stopped or become meaningless. Participants often report the experience feeling 'more real than real' or lasting 'an eternity' within a session of a few hours.
Noetic Quality
Profound sense of truth or insight — knowing something deeply and certainly, not through logical reasoning but through direct experience. William James (1902) identified this as a hallmark of mystical states.
Sacredness / Awe
Encounter with what feels sacred, holy, or divine — regardless of the person's prior religious belief. The Mystical Experience Questionnaire (MEQ30) measures this as a distinct factor from unity.
Positive Mood / Ineffability
Deep feelings of peace, joy, love, or bliss. Combined with the inability to adequately put the experience into words. Participants consistently describe the experience as among the most meaningful of their lives.
Global Legal Landscape
The legal status of psychedelics is shifting rapidly across the globe, creating a patchwork of decriminalization, medical access, religious exemption, and continuing prohibition.
Oregon legalized psilocybin-assisted therapy (Measure 109, 2020; services began 2023). Colorado passed Proposition 122 (2022) decriminalizing psilocybin, DMT, ibogaine, and mescaline, and creating regulated access. Over 20 cities have decriminalized psychedelics, including Denver, Oakland, Santa Cruz, Ann Arbor, and Washington D.C. Ketamine (Spravato) is FDA-approved. At the federal level, all classical psychedelics remain Schedule I.
In February 2023, Australia became the first country to officially recognize psychedelics as medicines. The TGA (Therapeutic Goods Administration) rescheduled psilocybin and MDMA, allowing authorized psychiatrists to prescribe them for treatment-resistant depression and PTSD respectively. Treatment costs are high (estimated AUD $25,000+ per course) and access remains limited to a small number of approved practitioners.
Psilocybin truffles (sclerotia) remain legal, sold openly in 'smart shops' since magic mushrooms were banned in 2008. The Netherlands has become a major destination for psilocybin retreats, operating in a legal gray zone. Several companies offer guided therapeutic experiences with psilocybin truffles. The Dutch government is evaluating stricter regulation as retreat tourism grows.
Psilocybin mushrooms are unregulated (not explicitly illegal) in Jamaica, making it a hub for legal psilocybin retreats. Numerous luxury retreat centers operate openly (e.g., MycoMeditations, Silo Wellness). Costa Rica similarly has no specific laws against psilocybin, supporting a growing retreat industry. Both countries attract 'psychedelic tourists' from jurisdictions where these substances are prohibited.
Ayahuasca is legal for religious use, protected under freedom of religion. Santo Daime and UDV churches operate legally. Brazil also does not schedule psilocybin mushrooms. Ibogaine treatment is unregulated and a growing number of clinics offer addiction treatment. However, cannabis and most synthetic drugs remain strictly controlled.
The plants are teachers. They have been teaching humans since before language.
— Mazatec saying
Psychedelics & SBNR — Spirituality Without Institutions
For the growing SBNR population — those who seek spiritual experience outside organized religion — psychedelics offer a direct, empirical path to the sacred. But this path carries both profound promise and serious responsibility.
Catalyst, Not Replacement
Psychedelic experiences often serve as catalysts for ongoing spiritual practice. Research by Griffiths et al. (2018) found that participants who had psilocybin-induced mystical experiences showed increased engagement with meditation, prayer, and other spiritual practices months afterward. The experience opens a door; the individual must choose to walk through it.
Spiritual But Not Religious
The SBNR movement finds a natural ally in psychedelics. These substances can produce profound spiritual experiences outside any religious framework. A 2019 survey of psychedelic users (Haijen et al., Psychopharmacology) found that psychedelic use was associated with increased 'spiritual awareness' but not with increased religious practice. People seek the sacred without the institution.
The Stoned Ape Hypothesis
Ethnobotanist Terence McKenna proposed (1992) that psilocybin mushrooms played a role in the evolution of human consciousness, language, and spirituality. While not widely accepted in mainstream science, the hypothesis has gained cultural traction. Archaeological evidence of psychedelic use (Tassili cave art ~7000 BCE, Eleusinian Mysteries, Soma/Haoma) suggests deep ties between entheogens and the origins of spiritual practice.
Risks & Ethical Considerations
Psychedelics are not without risks. Adverse effects include anxiety, paranoia, psychotic episodes (particularly in those predisposed to schizophrenia), HPPD (hallucinogen persisting perception disorder), and serotonin syndrome when combined with certain medications. Set and setting profoundly influence outcomes. The commercialization of indigenous plant medicines raises serious ethical questions about cultural appropriation, informed consent, and equitable benefit-sharing. Underground therapy carries additional risks of practitioner abuse. A responsible SBNR perspective must hold both the promise and the peril.
Decriminalization Movements
The global trend toward psychedelic decriminalization reflects a broader rethinking of drug policy. Portugal's 2001 decriminalization of all drugs is often cited as a model: drug-related deaths decreased, HIV infections among drug users fell by 95%, and overall use did not increase. While Portugal's policy addresses all drugs (not specifically psychedelics), it demonstrates that decriminalization does not lead to the feared outcomes.
In the US, grassroots organizations like Decriminalize Nature have led campaigns in over 100 cities. Their argument: naturally occurring psychoactive plants and fungi have been used by indigenous cultures for millennia and should not be criminalized. The movement draws parallels to cannabis legalization but faces unique challenges: psychedelics carry genuine risks for vulnerable populations, and commercialization threatens to strip these substances of their cultural and spiritual context.
Sources & References
- Griffiths, R. R. et al. “Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer.” Journal of Psychopharmacology, 30(12), 2016.
- Carhart-Harris, R. et al. “Trial of Psilocybin versus Escitalopram for Depression.” New England Journal of Medicine, 384, 2021.
- Mitchell, J. M. et al. “MDMA-assisted therapy for severe PTSD.” Nature Medicine, 27, 2021.
- Barrett, F. S. et al. “The Mystical Experience Questionnaire (MEQ30).” Journal of Psychopharmacology, 29(11), 2015.
- Strassman, R. DMT: The Spirit Molecule. Park Street Press, 2001.
- Barker, S. A. “N,N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen.” Frontiers in Neuroscience, 12, 2018.
- Szigeti, B. et al. “Self-blinding citizen science to explore psychedelic microdosing.” eLife, 10, 2021.
- Palhano-Fontes, F. et al. “Rapid antidepressant effects of ayahuasca in treatment-resistant depression.” Psychological Medicine, 49(4), 2019.
- Zarate, C. A. et al. “A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression.” Archives of General Psychiatry, 63(8), 2006.
- Brown, T. K. & Alper, K. “Treatment of opioid use disorder with ibogaine.” American Journal of Drug and Alcohol Abuse, 44(1), 2018.
- McKenna, T. Food of the Gods: The Search for the Original Tree of Knowledge. Bantam, 1992.
- Data Bridge Market Research. “Global Psychedelic Drugs Market Report.” 2023.
- Haijen, E. et al. “Predicting Responses to Psychedelics.” Psychopharmacology, 2019.
- Carhart-Harris, R. L. & Friston, K. J. “REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.” Pharmacological Reviews, 71(3), 2019. (Cited 1,078 times, OpenAlex 2026)
- Reiff, C. M. et al. “Psychedelics and Psychedelic-Assisted Psychotherapy.” American Journal of Psychiatry, 177(5), 2020.
- OpenAlex. Open index of scholarly works. 12,591 records for “psychedelics”; 687 for “psychedelic therapy + psilocybin.” Accessed March 2026.